Survival Analysis of Stage Ⅳ Metastatic Gastric Cancer Patients Treated with HangAm-Plus

Objective：To evaluate the efficacy of HangAm-Plus（HAP）on stageⅣmetastatic gastric cancer by analyzing the treated patients’overall survival outcome.Methods：Following the study eligibility,overall survival and one year survival rate of 44 stageⅣmetastatic gastric cancer patients who visited EastWest...

Full description

Saved in:
Bibliographic Details
Published in:Chinese journal of integrative medicine 2014, Vol.20 (1), p.49-55
Main Authors: Park, Jae-Woo, Yoon, Jeungwon, Cho, Chong-Kwan, Lee, Yeon-Weol, Yoo, Hwa-Seung
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Clinical Experience
Drugs, Chinese Herbal - adverse effects
Drugs, Chinese Herbal - therapeutic use
Female
HAP
Humans
Male
Medicine
Medicine & Public Health
Middle Aged
Neoplasm Metastasis
Neoplasm Staging
Stomach Neoplasms - drug therapy
Stomach Neoplasms - pathology
Survival Analysis
Young Adult
患者
生存分析
综合治疗
联合治疗
胃癌
舞台
转移性
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective：To evaluate the efficacy of HangAm-Plus（HAP）on stageⅣmetastatic gastric cancer by analyzing the treated patients’overall survival outcome.Methods：Following the study eligibility,overall survival and one year survival rate of 44 stageⅣmetastatic gastric cancer patients who visited EastWest Cancer Center（EWCC）were analyzed.The study consisted of two arms：HAP treatment only（n=18）and combined treatment of concurrent conventional chemotherapy and HAP（n=26）.Patient characteristics by gender,age,surgical intervention,Eastern Cooperative Oncology Group（ECOG）score,treatment duration（〈4 weeks or≥4 weeks）,and lines of the chemotherapy received were assessed.Treatment related side effects were also assessed.Results：The median survival of combined group was longer（10.0 months）than that of HAP group（5.1 months）.One-year survival rate of combined treatment group and HAP group was 38.5%±9.5%and 33.3%±11.1%,respectively（P〉0.05）.One-year survival rate of those received more and less than 4-week treatment was 57.1%±18.7%and 8.3%±8.0%,respectively（P=0.001）.Conclusions：The study supports the safety and potential efficacy of HAP treatment in prevention of chemo-related side effects for stageⅣmetastatic gastric cancer treated with conventional chemotherapy.Further studies are needed to investigate and confirm the results before applying the treatment in clinical settings.
ISSN:1672-0415
1993-0402
DOI:10.1007/s11655-012-1084-0